Navigation Links
Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors
Date:3/24/2009

BROOMFIELD, Colo., March 24 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today that Thomas Werner, Ph.D. has been elected to its board of directors.

Since 2001, Dr. Werner has been a managing director and senior vice president of GlaxoSmithKline (GSK) and has served as CEO of the GSK Foundation until earlier this year. He led the Pharmaceutical Research Manufacturers of America (PhRMA) in Germany as its chairman through November 2008. He began his pharmaceutical career with Squibb Pharma Germany where he held sales, marketing and brand management positions from 1983-1989 and later held executive management positions at Bristol-Myers Squibb. Dr. Werner earned his Ph.D. in chemistry at the University of Gottingen in Germany.

Dr. Werner was instrumental in the successful growth strategies and leadership of the German subsidiaries of GSK and Bristol-Myers Squibb. He grew sales of the ACE inhibitor, Captopril, to become the largest pharmaceutical product in Germany, and developed Viani, an asthma drug, into one of the leading pharmaceutical products in Germany.

Dr. Werner co-founded the Genetic Research Center, a joint venture with the Max Planck Institute for Psychiatry and the Ludwig-Maximilians-University, both in Munich. He is a member of the Board of Trustees of the Paul Ehrlich Association and the Robert Koch Foundation.

"We are delighted to welcome Dr. Werner to our board of directors," said Steve Orndorff, Ph.D., Accera's founder and CEO. "Thomas has a demonstrated record of success in the management and leadership of European subsidiaries of internationally acclaimed pharmaceutical companies. With Accera's recent US product launch of Axona(TM) for Alzheimer's disease, Dr. Werner's experience in the commercialization of several highly successful drug products will be invaluable."

'/>"/>

SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
2. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
3. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
4. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
5. eResearchTechnology, Inc. to Present at the Thomas Weisel Healthcare Conference on September 4th, 2008
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
8. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
9. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
11. Volcano Presentation at Thomas Weisel Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... leader in Personalized Medicine, is excited to announce ... Genetic Testing to Optimize the Management of Pain”. ... available at Medscape.com for the next year. The ... professionals how to recognize inadequate pain treatments, integrate ...
(Date:3/4/2015)... Follow us on LinkedIn - ... growing technologies in the life sciences industry. Growing global ... growth in nucleic acid detection technologies like qPCR and ... will continue to benefit the qPCR and dPCR instruments ... pharma, biotech, food & beverage to animal feed, will ...
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... SHANGHAI, July 15 /PRNewswire-Asia-FirstCall/ -- ... a leading Chinese firm,specializing in the manufacture, research, development, ... results for,the fourth quarter and fiscal year ended March ... 2009 Highlights, -- Net sales increased ...
... Mass., July 14 The Huffington Post -- ,The ... with astronomer Bob Berman) " Biocentrism." The article by ... universe. The Huffington Post is ranked the most powerful ... over 20 million thought-leaders, and has featured celebrity contributors from politics ...
... EnVivo Pharmaceuticals today announced at the Alzheimer,s Association 2009 ... deficits observed in an Alzheimer,s disease transgenic animal model after ... data was disclosed as part of the preclinical characterization of ... , EVP-0962 is a proprietary small molecule that ...
Cached Biology Technology:China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13New Scientific Worldview 'Biocentrism' Featured in The Huffington Post - #1 Weblog in the World 2EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator 2
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... researchers are developing two inexpensive technologies that may be ... recent outbreak of E. coli in contaminated spinach. , ... , The first method uses a laser to ... about three times faster and one-tenth as expensive as ...
... how much detail one remembers of an event depends on ... "package" the memory. , The research may help to explain ... as a car accident, and yet vividly recall all of ... using functional magnetic resonance imaging (fMRI), the scientists were able ...
... (UC) environmental health researchers have determined that firefighters are ... cancer than workers in other fields. , Their findings ... the past didn't do a good job in protecting ... the researchers say. , The researchers found, for ...
Cached Biology News:Researchers develop technologies to devour food pathogens 2Researchers develop technologies to devour food pathogens 3Memories: It's all in the packaging, scientists say 2Firefighters face increased risk for certain cancers 2
... For nucleofection of optimized cell lines ... protocol including the nucleofection parameters. Nucleofector ... with the Nucleofector Device., Different cell ... kit. The corresponding efficiencies and viabilities ...
... used with its manganese-containing reaction buffer, converts ... of short (1825 bp) interfering RNAs (siRNA) ... 1.3 units (1 l) of ShortCut RNase ... of dsRNA into siRNA suitable for RNA ...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: